Related Experiment Video

Updated: Jun 17, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

697

Effect of a polyherbal Unani formulation on left ventricular diastolic dysfunction in hypertensive patients - a

Asia Khanum1, Javed Ali Khan2, Arisha Shahid3

  • 1Department of Moalajat, Rehbar Ayurvedic & Unani Tibbi Medical College Hospital and Research Centre, Sangrur, Punjab, India.

Drug Metabolism and Personalized Therapy
|August 13, 2024
PubMed

Insights

A Unani formulation significantly improved left ventricular diastolic function and reduced symptoms like dyspnea and fatigue in patients with diastolic dysfunction. Further research is needed to confirm long-term efficacy and optimal treatment strategies.

Area of Science:

  • Integrative Medicine
  • Cardiology
  • Pharmacology

Background:

  • Diastolic dysfunction is a key factor linking hypertension to heart failure, with a rising prevalence of heart failure with preserved ejection fraction (HFpEF).
  • HFpEF poses significant morbidity and mortality risks, yet evidence-based therapies and clinical trials remain limited.
  • This study addresses the need for effective treatments for diastolic dysfunction by investigating a Unani formulation.

Purpose of the Study:

  • To evaluate the efficacy of a polyherbal Unani formulation in improving left ventricular diastolic function.
  • To assess the impact of the Unani formulation on symptoms associated with diastolic dysfunction, such as dyspnea and fatigability.

Main Methods:

  • A randomized, placebo-controlled clinical trial was conducted with 35 participants (18 test, 17 control).
  • The test group received a Unani formulation and *Borago officinalis* extract for eight weeks.
  • The control group received a placebo, with follow-ups every 15 days to monitor subjective and objective parameters.

Main Results:

  • The Unani formulation demonstrated significant improvement in dyspnea and diastolic function (p<0.05) compared to placebo.
  • Highly significant improvement was observed in easy fatigability (p=0.001).
  • A slight, non-significant improvement was noted in palpitations (p>0.05).

Conclusions:

  • The Unani formulation effectively enhances left ventricular diastolic function and alleviates associated symptoms.
  • Further research with extended follow-up is warranted to establish optimal treatment protocols for ventricular diastolic dysfunction within Unani medicine.
Abstract

Keywords:
Arq-e-GaozabanZoaf-e-QalbUnani medicineherbal formulationleft ventricular diastolic dysfunction

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.2K
Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

3.5K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
642
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
492
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
140